Peter Heerma - 02 May 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
CHIEF COMMERCIAL OFFICER
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol
TVTX
Transactions as of
02 May 2025
Net transactions value
-$37,280
Form type
4
Filing time
05 May 2025, 21:53:07 UTC
Previous filing
12 Feb 2025
Next filing
24 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Heerma Peter CHIEF COMMERCIAL OFFICER C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO /s/ Elizabeth E. Reed, Attorney-in-Fact 05 May 2025 0001789617

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Options Exercise +4,920 +3.9% 129,986 02 May 2025 Direct F1, F2
transaction TVTX Common Stock Sale $37,280 -1,771 -1.4% $21.05 128,215 05 May 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Performance-based restricted stock units Options Exercise $0 -4,920 -50% $0.000000 4,920 02 May 2025 Common Stock 4,920 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.
F2 Each PSU represents a contingent right to receive one share of the common stock of the Issuer.
F3 Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.